Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Biocatalytic Deracemisation of Atropisomeric Drug Candidates

Project description

Efficient production of chiral drugs

Some drugs and drug candidates exist in forms called atropisomers, in which slow rotation of a bond in the molecule creates two mirror-image versions. These forms behave differently, necessitating the development of ways to make drugs in single atropisomeric forms. However, current approaches present challenges, especially for complex, water-soluble molecules. The ERC-funded RAMESES project proposes to develop a new biocatalytic approach called enzymatic deracemisation that efficiently converts mixtures of atropisomers into a single desired form. Unlike traditional techniques, this method is sustainable, versatile and suitable for drug-like molecules. By partnering with industry, the project aims to demonstrate its potential to transform how pharmaceutical companies produce high-value atropisomeric drugs.

Objective

Drugs that are chiral due to slow bond rotation (atropisomeric) are becoming more prevalent, and atropisomerism is increasingly recognised as an asset rather than a hindrance in medicinal chemistry programmes. However, although some asymmetric routes to atropisomers are established, very few methods are applicable to ‘drug-like’ atropisomers – namely those that are heavily functionalised, hydrophilic and often heterocyclic target molecules, meaning that enantiomerically pure atropisomeric drug candidates are typically obtained by wasteful and inefficient resolution methods.
This proposal will address this problem by developing the concept of enzymatic deracemisation – discovered incidentally during an ERC AdG study of controlled molecular motion – to the atropisomer classes typically found in medicinal chemistry development programmes. In contrast to classical means of obtaining enantiopure atropisomers, this proposed biocatalytic method overcomes the yield and waste limitations of classical resolution and is uniquely applicable to the polar, water-soluble drug candidates for which existing asymmetric methods fail. The method stands out as sustainable, versatile and capable of making potential chiral drugs of enormous value and will be transformative for how the chemical and pharmaceutical sectors produce atropisomeric drug molecules. The originality of the project stems directly from a newly discovered chemical process unique to our laboratory. The Research Team is composed of diverse specialists in synthesis, biocatalysis, complex reaction networks and drug development. Development of the method will involve close partnership with industrial partners to identify enzyme classes, methods and target molecules for use as case-studies to quantify the benefits of the technology.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSITY OF BRISTOL
Net EU contribution
€ 150 000,00
Address
BEACON HOUSE QUEENS ROAD
BS8 1QU BRISTOL
United Kingdom
Region
South West (England) Gloucestershire, Wiltshire and Bristol/Bath area Bristol, City of
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)